Market Size of Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 3.94 Billion |
| Market Size (2029) | USD 5.25 Billion |
| CAGR (2024 - 2029) | 5.90 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Analysis
The Europe Glucagon-Like Peptide-1 Agonists Market size is estimated at USD 3.94 billion in 2024, and is expected to reach USD 5.25 billion by 2029, growing at a CAGR of 5.90% during the forecast period (2024-2029).
mainly as a result of new drug launches. Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway. Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication used in combination with diet and exercise to help treat type 2 diabetes. The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), brands (Byetta, Bydureon, Victoza, Trulicity, Lyxumia, and Ozempic) and Geography (Germany, Spain, Italy, France, United Kingdom, Russia, and Rest of Europe). The report offers the value (in USD million) and volume (in Units million) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.
| Drug | ||||
| ||||
| ||||
| ||||
| ||||
|
| Geography | |
| Germany | |
| Spain | |
| Italy | |
| France | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size Summary
The Europe GLP-1 Agonist Market is poised for significant growth, driven by the increasing prevalence of diabetes and the introduction of new pharmaceutical products. With a substantial portion of the European population affected by diabetes, the demand for effective treatment options is on the rise. The market is characterized by the presence of major pharmaceutical companies such as Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, which are actively contributing to the development and distribution of GLP-1 agonists. These medications are particularly beneficial for patients with type 2 diabetes, offering advantages such as weight loss and cardiovascular protection, which are crucial in managing the disease's complications. The market's expansion is further supported by government initiatives and collaborations aimed at improving diabetes care and management across the region.
Germany stands out within the European market due to its high prevalence of diabetes and advanced healthcare infrastructure. The country's regulatory environment, which includes stringent reimbursement and pricing policies, supports the growth of the GLP-1 agonist market by ensuring access to necessary treatments. The increasing awareness of diabetes and the ongoing development of non-insulin therapies are creating opportunities for market players to expand their presence. The market's growth trajectory is expected to continue, fueled by the introduction of innovative products and the strategic efforts of key industry players to enhance diabetes management solutions.
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drug
-
2.1.1 Exenatide
-
2.1.1.1 Byetta
-
2.1.1.2 Bydureon
-
-
2.1.2 Liraglutide
-
2.1.2.1 Victoza
-
-
2.1.3 Lixisenatide
-
2.1.3.1 Lyxumia
-
-
2.1.4 Dulaglutide
-
2.1.4.1 Trulicity
-
-
2.1.5 Semaglutide
-
2.1.5.1 Ozempic
-
-
-
2.2 Geography
-
2.2.1 Germany
-
2.2.2 Spain
-
2.2.3 Italy
-
2.2.4 France
-
2.2.5 United Kingdom
-
2.2.6 Russia
-
2.2.7 Rest of Europe
-
-
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size FAQs
How big is the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?
The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion in 2024 and grow at a CAGR of 5.90% to reach USD 5.25 billion by 2029.
What is the current Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size?
In 2024, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion.
